Add like
Add dislike
Add to saved papers

Neurological syndromes in systemic lupus erythematosus and their association with antiphospholipid syndrome.

BACKGROUND AND PURPOSE: In patients with systemic lupus erythematosus (SLE), severe neurological syndromes indicating central, peripheral or autonomic nervous system involvement are frequently seen. Antiphospholipid syndrome (APS) increases the risk of nervous system involvement. The aim of the study was to assess neurological manifestations occurring in patients with SLE and to evaluate their association with APS.

MATERIAL AND METHODS: One hundred thirty-seven patients (123 women and 14 men) with SLE were studied. Fifty out of 137 patients (43 women and 7 men) were diagnosed with APS. All patients underwent full neurological examination and diagnostics. Neurological syndromes were classified according to the standardized American College of Rheumatology (ACR) nomenclature.

RESULTS: Neurological syndromes were found in 89 cases out of 137 admitted SLE patients (64.96%). Headache was present in 52 patients (37.96%), polyneuropathy in 17 (12.41%), cerebrovascular disease in 13 (9.49%), seizures in 10 (7.3%), cranial neuropathy in 5 (3.65%), demyelinating syndrome in 5 (3.65%), mononeuropathy in 3 (2.19%), movement disorder in 3 (2.19%), and aseptic meningitis in 2 patients (1.46%). Our study indicated that 78% of patients with APS showed nervous system involvement as compared with 57.47% of SLE patients without APS (p=0.01).

CONCLUSIONS: Neurological syndromes occurring most frequently in SLE patients include headache, polyneuropathy and cerebrovascular diseases. Antiphospholipid syndrome increases the risk of nervous system involvement. We found that APS was strongly associated with neurological manifestations and in particular with cerebrovascular diseases and seizures.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app